Filipe Oliveira de Almeida1, Vagner Santana1, Daniel M Corcos2, Carlos Ugrinowitsch3, Carla Silva-Batista4,5,6. 1. Exercise Neuroscience Research Group, University of São Paulo, São Paulo, Brazil. 2. Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, USA. 3. Laboratory of Adaptations To Strength Training, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil. 4. Exercise Neuroscience Research Group, University of São Paulo, São Paulo, Brazil. csilvabatista@usp.br. 5. School of Arts, Sciences and Humanities of University of São Paulo, St. Arlindo Béttio, 1000, 03828-000, Vila Guaraciaba, São Paulo, Brazil. csilvabatista@usp.br. 6. Laboratory of Adaptations To Strength Training, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil. csilvabatista@usp.br.
Abstract
BACKGROUND: Evidence has demonstrated that endurance training (ET) reduces the motor signs of Parkinson's disease (PD). However, there has not been a comprehensive meta-analysis of studies to date. OBJECTIVE: The aim of this study was to compare the effect of ET versus nonactive and active control conditions on motor signs as assessed by either the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) or Movement Disorder Society-UPDRS-III (MDS-UPDRS-III). METHODS: A random-effect meta-analysis model using standardized mean differences (Hedges' g) determined treatment effects. Moderators (e.g., combined endurance and physical therapy training [CEPTT]) and meta-regressors (e.g., number of sessions) were used for sub-analyses. Methodological quality was assessed by the Physiotherapy Evidence Database. RESULTS: Twenty-seven randomized controlled trials (RCTs) met inclusion criteria (1152 participants). ET is effective in decreasing UPDRS-III scores when compared with nonactive and active control conditions (g = - 0.68 and g = - 0.33, respectively). This decrease was greater (within- and between-groups average of - 8.0 and - 6.8 point reduction on UPDRS-III scores, respectively) than the moderate range of clinically important changes to UPDRS-III scores (- 4.5 to - 6.7 points) suggested for PD. Although considerable heterogeneity was observed between RCTs (I2 = 74%), some moderators that increased the effect of ET on motor signs decreased the heterogeneity of the analyses, such as CEPTT (I2 = 21%), intensity based on treadmill speed (I2 = 0%), self-perceived exertion rate (I2 = 33%), and studies composed of individuals with PD and freezing of gait (I2 = 0%). Meta-regression did not produce significant relationships between ET dosage and UPDRS-III scores. CONCLUSIONS: ET is effective in decreasing UPDRS-III scores. Questions remain about the dose-response relationship between ET and reduction in motor signs.
BACKGROUND: Evidence has demonstrated that endurance training (ET) reduces the motor signs of Parkinson's disease (PD). However, there has not been a comprehensive meta-analysis of studies to date. OBJECTIVE: The aim of this study was to compare the effect of ET versus nonactive and active control conditions on motor signs as assessed by either the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) or Movement Disorder Society-UPDRS-III (MDS-UPDRS-III). METHODS: A random-effect meta-analysis model using standardized mean differences (Hedges' g) determined treatment effects. Moderators (e.g., combined endurance and physical therapy training [CEPTT]) and meta-regressors (e.g., number of sessions) were used for sub-analyses. Methodological quality was assessed by the Physiotherapy Evidence Database. RESULTS: Twenty-seven randomized controlled trials (RCTs) met inclusion criteria (1152 participants). ET is effective in decreasing UPDRS-III scores when compared with nonactive and active control conditions (g = - 0.68 and g = - 0.33, respectively). This decrease was greater (within- and between-groups average of - 8.0 and - 6.8 point reduction on UPDRS-III scores, respectively) than the moderate range of clinically important changes to UPDRS-III scores (- 4.5 to - 6.7 points) suggested for PD. Although considerable heterogeneity was observed between RCTs (I2 = 74%), some moderators that increased the effect of ET on motor signs decreased the heterogeneity of the analyses, such as CEPTT (I2 = 21%), intensity based on treadmill speed (I2 = 0%), self-perceived exertion rate (I2 = 33%), and studies composed of individuals with PD and freezing of gait (I2 = 0%). Meta-regression did not produce significant relationships between ET dosage and UPDRS-III scores. CONCLUSIONS: ET is effective in decreasing UPDRS-III scores. Questions remain about the dose-response relationship between ET and reduction in motor signs.
Authors: Brit Mollenhauer; Johannes Zimmermann; Friederike Sixel-Döring; Niels K Focke; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Tim Friede; Claudia Trenkwalder Journal: Mov Disord Date: 2018-11-23 Impact factor: 10.338
Authors: Matthew A Sacheli; Jason L Neva; Bimal Lakhani; Danielle K Murray; Nasim Vafai; Elham Shahinfard; Carolyn English; Siobhan McCormick; Katie Dinelle; Nicole Neilson; Jessamyn McKenzie; Michael Schulzer; Don C McKenzie; Silke Appel-Cresswell; Martin J McKeown; Lara A Boyd; Vesna Sossi; A Jon Stoessl Journal: Mov Disord Date: 2019-10-04 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Tanya Simuni; Andrew Siderowf; Shirley Lasch; Chris S Coffey; Chelsea Caspell-Garcia; Danna Jennings; Caroline M Tanner; John Q Trojanowski; Leslie M Shaw; John Seibyl; Norbert Schuff; Andrew Singleton; Karl Kieburtz; Arthur W Toga; Brit Mollenhauer; Doug Galasko; Lana M Chahine; Daniel Weintraub; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Vanessa Arnedo; Mark Frasier; Todd Sherer; Sohini Chowdhury; Kenneth Marek Journal: Mov Disord Date: 2018-03-23 Impact factor: 10.338
Authors: Charity G Patterson; Elizabeth Joslin; Alexandra B Gil; Wendy Spigle; Todd Nemet; Lana Chahine; Cory L Christiansen; Ed Melanson; Wendy M Kohrt; Martina Mancini; Deborah Josbeno; Katherine Balfany; Garett Griffith; Mac Kenzie Dunlap; Guillaume Lamotte; Erin Suttman; Danielle Larson; Chantale Branson; Kathleen E McKee; Li Goelz; Cynthia Poon; Barbara Tilley; Un Jung Kang; Malú Gámez Tansey; Nijee Luthra; Caroline M Tanner; Jacob M Haus; Giamila Fantuzzi; Nikolaus R McFarland; Paulina Gonzalez-Latapi; Tatiana Foroud; Robert Motl; Michael A Schwarzschild; Tanya Simuni; Kenneth Marek; Anna Naito; Codrin Lungu; Daniel M Corcos Journal: Trials Date: 2022-10-06 Impact factor: 2.728